Exploring MRD's Role in AML Therapy and Stemness's Impact on Chemotherapy Resistance

This chapter examines the critical role of measurable residual disease (MRD) in influencing maintenance therapy choices for patients with FLT3-ITD acute myeloid leukemia after transplantation. It highlights the correlation between MRD status and relapse rates, advocating for the use of FLT3 inhibitors like gilteritinib in patients with detectable MRD while discussing the impact of GATA-2 on chemotherapy resistance.